Bortezomib

CAS 179324-69-7 22 current records 4 historicalSmall Molecule

Who holds supplier records for Bortezomib? 22 organisations hold a current record for Bortezomib: an active US FDA Type II Drug Master File. A further 4 organisations have only historical (inactive) DMF filings. Recorded organisation countries for current records: India (12), China (4), Australia (1), Taiwan (1) and 1 other country (1); not recorded for 3.

Sources: FDA Drug Master File list, EDQM certification database, FDA Orange Book. Record updated 16 Nov 2026. How we read these records

Cite as: PharmaTek, “Bortezomib: DMF and CEP holder records”, record as of 16 Nov 2026, pharmatek.co.uk/directory/api/bortezomib

Reading the evidence

  • 22 current records

    Several organisations hold current DMFs or CEPs. Whether any is a usable source for your grade, scale and market still needs qualification.

  • Most recorded organisations are in India

    12 of the 19 current records with a recorded country list India. Organisation country is not necessarily the manufacturing site.

  • 11 with a company-level GMP certificate on record

    These organisations have at least one current EU or UK GMP certificate somewhere. It is not matched to the site that makes this substance; check the certificate's site and scope.

Current records (22)

Organisations holding an active US FDA Type II Drug Master File or a CEP for Bortezomib. Country is the organisation's recorded country, not necessarily the manufacturing site.

Need Bortezomib sourced and checked?

The Sourcing Desk contacts candidates, confirms current supply, grade and site, and screens each against its regulatory record, for a buyer-paid fixed fee and never a supplier commission.

Request sourcing help

Historical records (4)

Organisations whose Type II DMFs for Bortezomib are no longer active. These show a past filing, not current supply.

Show all 4 historical records
  • India · Inactive DMF 30264 · filed Mar 2016
  • China · Inactive DMF 27432 · filed Sept 2013
  • POLYMED THERAPEUTICS INC
    Inactive DMF 25740 · filed Jan 2012
  • Viwit Pharmaceutical Co., Ltd.
    China · Inactive DMF 22884 · filed Jun 2009

Overview

Bortezomib is a proteasome inhibitor used as an anticancer drug for the treatment of multiple myeloma and certain types of lymphoma. It works by interrupting the proteasome pathway, leading to cellular apoptosis in cancer cells.

Chemical identity

IUPAC name
[(1R)-3-methyl-1-[[(2S)-3-phenyl-2-(pyrazine-2-carbonylamino)propanoyl]amino]butyl]boronic acid
Canonical SMILES
B([C@H](CC(C)C)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)C2=NC=CN=C2)(O)O
InChIKey
GXJABQQUPOEUTA-RDJZCZTQSA-N
Synonyms
Velcade API, bortezomib accord, bortezomib hydrate, ldp-341, nsc-681239, ps-341, velcade

Pharmacologic class

As the US FDA states it for this active substance on product listings.

Established pharmacologic class
Proteasome Inhibitor
Mechanism of action
Proteasome Inhibitors

Therapeutic areas

OncologyMultiple Myeloma

Record history

No change to the current records between 13 Nov 2026 and 16 Nov 2026.

Get an email when these records change: at most one a week, only when something changed, and only after you confirm your address. All changes this week

What these records establish

  • An active DMF means a confidential file is held by the FDA and can be referenced; the FDA does not approve or disapprove DMFs.
  • A CEP confirms monograph suitability for the EU market; it is not a GMP certificate, and the holder may not be the manufacturer.
  • Historical records show a past filing, not current supply.
  • Company GMP certificates are matched to the organisation, not to the site making this substance.
  • A substance missing from these registers is not evidence that no supplier exists.

Frequently asked questions

Which organisations hold current supplier records for Bortezomib?

22 organisations hold an active US FDA Type II Drug Master File or a CEP for Bortezomib: MSN Laboratories Private Limited (India), SHILPA PHARMA LIFESCIENCES LTD (India), APICORE LLC (A WHOLLY OWNED SUB OF RK PHARMA INC), ARTHUR GROUP LLC (Australia), BIOPHORE INDIA PHARMACEUTICALS PRIVATE LIMITED (India), Dr. Reddy's Laboratories Ltd. (India), Gland Chemicals Private Limited (India) and Granules India Limited (India), and 14 more listed on this page. A DMF or CEP shows a regulatory filing, not current commercial availability, and the holder is not necessarily the manufacturing site.

Which Bortezomib Drug Master Files are active?

MSN Laboratories Private Limited (DMF 27569, 35755), SHILPA PHARMA LIFESCIENCES LTD (DMF 36821, 24944), APICORE LLC (A WHOLLY OWNED SUB OF RK PHARMA INC) (DMF 22922), ARTHUR GROUP LLC (DMF 38777), BIOPHORE INDIA PHARMACEUTICALS PRIVATE LIMITED (DMF 29506), Dr. Reddy's Laboratories Ltd. (DMF 23996), Gland Chemicals Private Limited (DMF 26440) and Granules India Limited (DMF 34445) and 14 more. The FDA does not approve or disapprove DMFs; an active DMF can be referenced in an application once its holder issues a letter of authorisation.

What do the historical Bortezomib records mean?

4 organisations have only inactive Type II DMFs for Bortezomib. An inactive DMF records that a filing once existed; it does not show that the organisation supplies the substance today.

How do I qualify a Bortezomib supplier?

Confirm the DMF or CEP is current and covers your grade, obtain the letter of authorisation, identify the actual manufacturing site and check its GMP certificate and FDA inspection history, audit the site or review a recent audit, and run comparable requests for information across more than one candidate.

For suppliers

Do you supply Bortezomib?

Send a link to a certificate, registration or filing we have missed or got wrong. We check it against the issuing register before changing anything; information we cannot check against a register is shown as supplier-reported.

Free. Payment never buys an evidence status.